Real-world outcomes of haplo-HSCT with post-transplant cyclophosphamide in pediatric hematologic malignancies: a study on behalf of SFGM-TC and SFCE

doi:10.1038/s41409-025-02584-4

. 2025 Jun;60(6):917-920.

doi: 10.1038/s41409-025-02584-4. Epub 2025 Apr 13.

Real-world outcomes of haplo-HSCT with post-transplant cyclophosphamide in pediatric hematologic malignancies: a study on behalf of SFGM-TC and SFCE

Charlotte Calvo^#^{1

2}, Cléo Hautefeuille^#³, Loïc Vasseur^{4

5}, Florian Chevillon⁵, Charlotte Nazon⁶, Benedicte Bruno⁷, Marc Ansari^{8

9}, Arthur Sterin¹⁰, Anne Sirvent¹¹, Audrey Grain¹², Marie Angoso¹³, Virginie Gandemer¹⁴, Pascale Schneider¹⁵, Carine Halfon-Domenech¹⁶, Pierre-Simon Rohrlich¹⁷, Cécile Pochon¹⁸, Catherine Paillard⁶, Stephanie Nguyen Quoc¹⁹, Nicole Raus²⁰, Marion Strullu³, Françoise Méchinaud³, Nathalie Dhedin⁵, Jean-Hugues Dalle^{3

21}

Affiliations

¹ Pediatric Hematology and Immunology Department, Robert Debré Hospital, GHU APHP Nord Université Paris Cité, Paris, France. charlotte.calvo@aphp.fr.
² TIGITH team, INSERM UMR-1342, Institut de Recherche Saint-Louis, Paris, France. charlotte.calvo@aphp.fr.
³ Pediatric Hematology and Immunology Department, Robert Debré Hospital, GHU APHP Nord Université Paris Cité, Paris, France.
⁴ ECSTRRA team, Centre for Research in Epidemiology and Statistics, INSERM U1153, Université Paris Cité, Paris, France.
⁵ Adolescents and Young Adults Hematology Unit, Saint Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
⁶ Department of Pediatric Hematology-oncology, University Hospital of Strasbourg, Strasbourg, France.
⁷ Department of Pediatric Hematology-oncology, Jeanne de Flandre Hospital, Lille, France.
⁸ Department of Women, Children and Adolescents, Division of Pediatric Oncology and Hematology, Geneva University Hospital, 1205, Geneva, Switzerland.
⁹ Cansearch Research platform for pediatric oncology and hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland.
¹⁰ Department of pediatric hematology, immunology and oncology, La Timone Children's Hospital, Marseille, France.
¹¹ Department of Pediatric Hematology and Oncology, University Hospital, Montpellier, France.
¹² Department of Pediatric Hematology and Oncology, University Hospital of Nantes, Nantes, France.
¹³ Department of Pediatric Hematology and Oncology, University Hospital of Bordeaux, Bordeaux, France.
¹⁴ Department of Pediatric Hematology and Oncology, University Hospital of Rennes, Rennes, France.
¹⁵ Pediatric Hematology and Oncology Department, Unviversity hospital of Rouen, Rouen, France.
¹⁶ Pediatric Hematology and Immunology Department, Institut d'Hémato-Oncologie Pédiatrique (IHOP) Hospices civils de Lyon, Lyon, France.
¹⁷ Pediatric Hematology and Oncology Department, University Hospital L'Archet, Nice, France.
¹⁸ Department of Pediatric Onco-Hematology, Hôpital d'Enfants de Brabois, Vandoeuvre Les Nancy, France.
¹⁹ Hematology Department, Pitie-Salpetriere Hospital, 75013, Paris, France.
²⁰ Hôpital Lyon Sud, SFGM-TC, Lyon, France.
²¹ TIGITH team, INSERM UMR-1342, Institut de Recherche Saint-Louis, Paris, France.

^# Contributed equally.

PMID: 40223009
DOI: 10.1038/s41409-025-02584-4

Real-world outcomes of haplo-HSCT with post-transplant cyclophosphamide in pediatric hematologic malignancies: a study on behalf of SFGM-TC and SFCE

Charlotte Calvo et al. Bone Marrow Transplant. 2025 Jun.

. 2025 Jun;60(6):917-920.

doi: 10.1038/s41409-025-02584-4. Epub 2025 Apr 13.

Authors

Affiliations

¹ Pediatric Hematology and Immunology Department, Robert Debré Hospital, GHU APHP Nord Université Paris Cité, Paris, France. charlotte.calvo@aphp.fr.
² TIGITH team, INSERM UMR-1342, Institut de Recherche Saint-Louis, Paris, France. charlotte.calvo@aphp.fr.
³ Pediatric Hematology and Immunology Department, Robert Debré Hospital, GHU APHP Nord Université Paris Cité, Paris, France.
⁴ ECSTRRA team, Centre for Research in Epidemiology and Statistics, INSERM U1153, Université Paris Cité, Paris, France.
⁵ Adolescents and Young Adults Hematology Unit, Saint Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
⁶ Department of Pediatric Hematology-oncology, University Hospital of Strasbourg, Strasbourg, France.
⁷ Department of Pediatric Hematology-oncology, Jeanne de Flandre Hospital, Lille, France.
⁸ Department of Women, Children and Adolescents, Division of Pediatric Oncology and Hematology, Geneva University Hospital, 1205, Geneva, Switzerland.
⁹ Cansearch Research platform for pediatric oncology and hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland.
¹⁰ Department of pediatric hematology, immunology and oncology, La Timone Children's Hospital, Marseille, France.
¹¹ Department of Pediatric Hematology and Oncology, University Hospital, Montpellier, France.
¹² Department of Pediatric Hematology and Oncology, University Hospital of Nantes, Nantes, France.
¹³ Department of Pediatric Hematology and Oncology, University Hospital of Bordeaux, Bordeaux, France.
¹⁴ Department of Pediatric Hematology and Oncology, University Hospital of Rennes, Rennes, France.
¹⁵ Pediatric Hematology and Oncology Department, Unviversity hospital of Rouen, Rouen, France.
¹⁶ Pediatric Hematology and Immunology Department, Institut d'Hémato-Oncologie Pédiatrique (IHOP) Hospices civils de Lyon, Lyon, France.
¹⁷ Pediatric Hematology and Oncology Department, University Hospital L'Archet, Nice, France.
¹⁸ Department of Pediatric Onco-Hematology, Hôpital d'Enfants de Brabois, Vandoeuvre Les Nancy, France.
¹⁹ Hematology Department, Pitie-Salpetriere Hospital, 75013, Paris, France.
²⁰ Hôpital Lyon Sud, SFGM-TC, Lyon, France.
²¹ TIGITH team, INSERM UMR-1342, Institut de Recherche Saint-Louis, Paris, France.

^# Contributed equally.

PMID: 40223009
DOI: 10.1038/s41409-025-02584-4

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests. Ethics approval and patient consent: Patients or legal guardians provided written informed consent for data collection and use for analysis, in accordance with the Declaration of Helsinki. This study was approved by SFGM-TC and SFCE HSCT committees and registered on Health Data Hub (F20230327154245).

References

1. Ruggeri A, Galimard JE, Paina O, Fagioli F, Tbakhi A, Yesilipek A, et al. Outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with acute lymphoblastic leukemia. Transpl Cell Ther. 2021;27:424.e1–424.e9. - DOI
1. Fierro-Pineda JC, Tsai HL, Blackford A, Cluster A, Caywood E, Dalal J, et al. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv. 2023;7:5639–48. - DOI - PubMed - PMC
1. Ruggeri A, Santoro N, Galimard JE, Kalwak K, Algeri M, Zubarovskaya L, et al. Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study. Haematologica. 2024;109:2122–30. - PubMed - PMC
1. Kawahara Y, Morimoto A, Inagaki J, Koh K, Noguchi M, Goto H, et al. Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors. Bone Marrow Transplant. 2021;56:357–67. - DOI - PubMed
1. Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39:295–307. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

[1] Ruggeri A, Galimard JE, Paina O, Fagioli F, Tbakhi A, Yesilipek A, et al. Outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with acute lymphoblastic leukemia. Transpl Cell Ther. 2021;27:424.e1–424.e9. - DOI

[2] Ruggeri A, Galimard JE, Paina O, Fagioli F, Tbakhi A, Yesilipek A, et al. Outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with acute lymphoblastic leukemia. Transpl Cell Ther. 2021;27:424.e1–424.e9. - DOI

[3] Fierro-Pineda JC, Tsai HL, Blackford A, Cluster A, Caywood E, Dalal J, et al. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv. 2023;7:5639–48. - DOI - PubMed - PMC

[4] Fierro-Pineda JC, Tsai HL, Blackford A, Cluster A, Caywood E, Dalal J, et al. Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias. Blood Adv. 2023;7:5639–48. - DOI - PubMed - PMC

[5] Ruggeri A, Santoro N, Galimard JE, Kalwak K, Algeri M, Zubarovskaya L, et al. Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study. Haematologica. 2024;109:2122–30. - PubMed - PMC

[6] Ruggeri A, Santoro N, Galimard JE, Kalwak K, Algeri M, Zubarovskaya L, et al. Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study. Haematologica. 2024;109:2122–30. - PubMed - PMC

[7] Kawahara Y, Morimoto A, Inagaki J, Koh K, Noguchi M, Goto H, et al. Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors. Bone Marrow Transplant. 2021;56:357–67. - DOI - PubMed

[8] Kawahara Y, Morimoto A, Inagaki J, Koh K, Noguchi M, Goto H, et al. Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors. Bone Marrow Transplant. 2021;56:357–67. - DOI - PubMed

[9] Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39:295–307. - DOI - PubMed

[10] Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39:295–307. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Real-world outcomes of haplo-HSCT with post-transplant cyclophosphamide in pediatric hematologic malignancies: a study on behalf of SFGM-TC and SFCE

Affiliations

Real-world outcomes of haplo-HSCT with post-transplant cyclophosphamide in pediatric hematologic malignancies: a study on behalf of SFGM-TC and SFCE

Authors

Affiliations

Conflict of interest statement

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources